• Consensus Rating: Buy
  • Consensus Price Target: $44.71
  • Forecasted Upside: 112.02 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$21.09
▲ +0.66 (3.23%)

This chart shows the closing price for OPRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New OptimizeRx Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OPRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OPRX

Analyst Price Target is $44.71
▲ +112.02% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for OptimizeRx in the last 3 months. The average price target is $44.71, with a high forecast of $76.00 and a low forecast of $16.00. The average price target represents a 112.02% upside from the last price of $21.09.

This chart shows the closing price for OPRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 polled investment analysts is to buy stock in OptimizeRx. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/8/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/6/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/5/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/5/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/3/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/1/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/31/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/30/2022

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/31/2022Stifel NicolausInitiated CoverageBuy$19.00Low
8/10/2022SVB LeerinkLower TargetOutperform$38.00 ➝ $30.00Low
8/10/2022Piper SandlerLower TargetNeutral$29.00 ➝ $16.00Low
7/20/2022B. RileyLower TargetBuy$71.00 ➝ $56.00Low
7/15/2022SVB LeerinkInitiated CoverageOutperform$38.00Low
7/1/2022Piper SandlerInitiated CoverageNeutral$29.00Low
5/5/2022Royal Bank of CanadaLower Target$100.00 ➝ $50.00High
5/5/2022Roth CapitalLower Target$112.00 ➝ $66.00High
2/16/2022Lake Street CapitalLower TargetBuy$98.00 ➝ $76.00Medium
11/10/2021Roth CapitalBoost TargetBuy$85.00 ➝ $112.00Low
11/10/2021Royal Bank of CanadaBoost TargetOutperform$67.00 ➝ $100.00Medium
11/9/2021William BlairReiterated RatingOutperformHigh
10/18/2021B. RileyReiterated RatingBuy$102.00High
8/5/2021B. RileyBoost TargetBuy$80.00 ➝ $95.00High
5/7/2021B. RileyBoost TargetBuy$75.00 ➝ $80.00High
4/12/2021Royal Bank of CanadaInitiated CoverageOutperform$65.00Low
2/25/2021B. RileyBoost TargetBuy$60.00 ➝ $75.00High
2/25/2021Roth CapitalBoost TargetTop Pick ➝ Buy$70.00 ➝ $85.00High
1/26/2021Lake Street CapitalBoost TargetBuy$40.00 ➝ $54.00High
1/7/2021Lake Street CapitalBoost Target$26.00 ➝ $40.00N/A
1/7/2021Roth CapitalBoost TargetTop Pick ➝ Buy$40.00 ➝ $70.00N/A
1/4/2021B. RileyBoost TargetOutperform ➝ Buy$34.00 ➝ $50.00N/A
11/10/2020Lake Street CapitalBoost TargetBuy$21.00 ➝ $26.00Medium
11/10/2020B. RileyBoost TargetBuy$30.00 ➝ $34.00Medium
9/14/2020Roth CapitalBoost TargetBuy$30.00 ➝ $40.00High
8/6/2020B. RileyBoost Target$22.00 ➝ $28.00Low
8/6/2020Lake Street CapitalBoost TargetBuy$17.00 ➝ $20.00High
6/8/2020Lake Street CapitalBoost TargetReduce ➝ Buy$14.00 ➝ $17.00Medium
5/5/2020B. RileyBoost TargetBuy$18.00 ➝ $22.00High
4/7/2020B. RileyLower TargetBuy$20.00 ➝ $18.00Medium
1/3/2020William BlairInitiated CoverageOutperformLow
12/30/2019B. RileyLower TargetBuy$21.00 ➝ $20.00High
1/3/2019William BlairInitiated CoverageOutperform ➝ OutperformHigh
9/28/2018Roth CapitalBoost TargetBuy$22.50 ➝ $25.00N/A
9/17/2018Lake Street CapitalBoost TargetBuy$18.00Medium
8/8/2018B. RileyBoost TargetBuy ➝ Buy$15.00 ➝ $17.00Medium
8/8/2018Lake Street CapitalBoost TargetBuy$14.00High
7/10/2018B. RileyReiterated RatingBuyHigh
7/10/2018B. RileyInitiated CoverageBuy$15.00N/A
6/25/2018Lake Street CapitalBoost TargetBuy ➝ Positive$12.00Low
6/18/2018Roth CapitalReiterated RatingBuyMedium
6/18/2018Roth CapitalInitiated CoverageBuy$18.00N/A
2/28/2018Lake Street CapitalBoost TargetBuy$2.50High
(Data available from 12/1/2017 forward)

News Sentiment Rating

0.50 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
5/5/2022
  • 6 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
6/4/2022
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/4/2022
  • 3 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/3/2022
  • 11 very positive mentions
  • 11 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
9/2/2022
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/2/2022
  • 4 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/1/2022
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/1/2022

Current Sentiment

  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
OptimizeRx logo
OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers, and patients. The company's products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-prescribe systems; and brand awareness and therapeutic support messaging services, such as brand awareness messages, reminder ads, and therapeutic support and unbranded messages. It also offers brand support services, which focuses on educating and working with pharmaceutical manufacturers on identifying, formulating, and implementing eRx media strategies, including drug file integration, sales force training, and strategy development services for promoting their products. In addition, the company operates cloud based Mobile Health Messenger platform that provides interactive health messaging for enhanced medication adherence and care coordination; and HIPAA-compliant automated mobile messaging platform, which allows pharmaceutical manufactures and related entities to directly engage with patients to enhance regimen compliance. Further, it offers patient programs with treatment and affordability information, lifestyle and condition trackers, internet device connectivity, forms, and surveys. Additionally, the company provides evidence-based physician engagement solution applied to real-world data to assist healthcare providers in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations. It also offers therapy initiation workflow focused on accelerating patient access to treatments where time-consuming medical documentation is required of HCPs prior to pharmacies dispensing prescribed drugs. The company was found in 2006 and is headquartered in Rochester, Michigan.
Read More

Today's Range

Now: $21.09
Low: $19.58
High: $21.22

50 Day Range

MA: $16.73
Low: $13.74
High: $22.04

52 Week Range

Now: $21.09
Low: $13.33
High: $69.84

Volume

184,548 shs

Average Volume

218,276 shs

Market Capitalization

$361.76 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.81

Frequently Asked Questions

What sell-side analysts currently cover shares of OptimizeRx?

The following sell-side analysts have issued research reports on OptimizeRx in the last twelve months: B. Riley, Lake Street Capital, Piper Sandler, Roth Capital, Royal Bank of Canada, Stifel Nicolaus, SVB Leerink LLC, and TheStreet.
View the latest analyst ratings for OPRX.

What is the current price target for OptimizeRx?

7 Wall Street analysts have set twelve-month price targets for OptimizeRx in the last year. Their average twelve-month price target is $44.71, suggesting a possible upside of 112.0%. Lake Street Capital has the highest price target set, predicting OPRX will reach $76.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $16.00 for OptimizeRx in the next year.
View the latest price targets for OPRX.

What is the current consensus analyst rating for OptimizeRx?

OptimizeRx currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OPRX will outperform the market and that investors should add to their positions of OptimizeRx.
View the latest ratings for OPRX.

What other companies compete with OptimizeRx?

Other companies that are similar to OptimizeRx include Rimini Street, Edgio, Gravity, DHI Group and ASAP. Learn More about companies similar to OptimizeRx.

How do I contact OptimizeRx's investor relations team?

OptimizeRx's physical mailing address is 400 WATER STREET SUITE 200, ROCHESTER MI, 48307. The company's listed phone number is (248) 651-6568 and its investor relations email address is [email protected] The official website for OptimizeRx is www.optimizerx.com. Learn More about contacing OptimizeRx investor relations.